Sign in
Taking people in South KoreaPhase 3

Blood pressure targets after clot removal in acute ischemic stroke

Tests whether raising blood pressure works better than standard control in stroke patients.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
Status
Recruiting
Phase
Phase 3
People taking part
176 people, planned
Started
1 Oct 2024
Expected to end
3 Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BP lowering drugs (nicardipine, labetalol, urapidil)
  • BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 or older who had a stroke caused by a blocked brain artery. They had a clot-removal procedure that reopened the artery, and their blood pressure then stayed low.

Age
20 years or older
Sex
All sexes can join.
Disease stage
Acute ischemic stroke with a large artery blocked (ICA, M1, M2, A1, P1, VA or BA). The artery was successfully reopened by thrombectomy (TICI 2b or TICI 3).
Earlier treatment
Must have had thrombectomy through the artery (intraarterial thrombectomy) with successful reopening.
Biomarker or test result
Systolic blood pressure stays below 150 mmHg on measurements taken less than 10 minutes apart within 3 hours after the artery reopened. Mean systolic pressure is below 150 mmHg within 2 hours (two measurements at least 2 minutes apart).

Main reasons for not taking part

  • Reopening of the artery failed (TICI 2a or lower)
  • Bleeding in the brain with symptoms before enrolment
  • Disability before the stroke (mRS 3 or higher)
  • Heart failure with ejection fraction below 40%
  • Pregnant

The registry criteria, word for word

Show all 23 criteriaShow less

Other criteria

  • <Inclusion Criteria>
  • Age ≥20 years
  • Acute ischemic stroke patients who underwent intraarterial thrombectomy for large vessel occlusion. (ICA, M1, M2, A1, P1, VA and BA)
  • Patients with successful recanalization after intraarterial thrombectomy (TICI 2b or TICI 3)
  • Patients with sustained systolic blood pressure (SBP) <150 mm Hg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion
  • Patients with mean SBP <150 mmHg within 2 hours after successful recanalization (two measurements ≥2 minutes apart); <Exclusion Criteria>
  • Age <20
  • Patients who failed recanalization of the intracranial artery after endovascular thrombectomy (modified TICI ≤ 2a)
  • Patients with systolic blood pressure ≥ 150 mmHg after successful recanalization
  • Patients unable to receive antihypertensive medication post-thrombectomy or in whom the investigator believes aggressive blood pressure control could have adverse effects, such as increased risk of hemorrhage
  • Patients who developed symptomatic intracranial hemorrhage before study enrollment, after successful recanalization
  • Patients with contraindications to Phenylephrine
  • Patients with contraindications to antihypertensive medications
  • Patients with pre-stroke functional disability (modified Rankin Scale, mRS ≥3)
  • Patients with heart failure and reduced cardiac output, with an ejection fraction (EF) <40%
  • Patients with end-stage renal disease requiring renal replacement therapy, or chronic kidney disease stage 4 with an eGFR <30 mL/min
  • Patients currently taking monoamine oxidase (MAO) inhibitors
  • Patients with persistent bradycardia with a heart rate <45 bpm
  • Pregnant patients
  • Patients with severe medical or surgical comorbidities, including but not limited to: terminal cancer with life expectancy <6 months, severe cardiac or aortic disease, severe hematologic disorders, advanced chronic heart failure, severe pneumonia, or sepsis
  • Patients who do not consent to participate in the study
  • Patients participating in another study that does not allow co-enrollment
  • Patients whom the investigator deems unsuitable for study participation for any reason

Where in South Korea

  • Department of Neurology, Yonsei University College of MedicineSeoul, South KoreaContact: Hyo Suk Nam, MD, PhDTaking people

About the trial

What the trial wants to find out

Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.

Read full original descriptionShow less

Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in patients with sustained systolic blood pressure (SBP) <150 mmHg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.

This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at less than 160 mmHg) or a standard BP control group (systolic BP at or below 180 mmHg).

The 2 groups in the trial

  • Conventional BP magnagement group (SBP ≤180 mmHg)Existing treatment, for comparison

    Treatment: BP lowering drugs (nicardipine, labetalol, urapidil)

  • Intensive BP raising group (20% increase in SBP, maximum of 160 mmHg )Existing treatment, for comparison

    Treatment: BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
Plain-language title
Blood pressure targets after clot removal in acute ischemic strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 February 2026